Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.
BioDelivery Sciences is looking at a possible $60 million boost to programs in its lineup including the launch of its opioid dependence film Bunavail and continue on the approval path for its pain gel for diabetic neuropathy.
Raleigh, NC's BioDelivery Sciences has signed a deal to trade 7.5 million shares for $60 million, planning to spend the lion's share of the proceeds to launch Bunavail, a gel designed to treat opioid dependence.
North Carolina's BioDelivery Sciences International locked down $20 million in debt financing, cash the company will use to develop two treatments with proprietary drug delivery methods.
BioDelivery Sciences secured rights from Arcion Therapeutics to commercialize the company's first-of-its-kind topical gel to treat painful diabetic neuropathy.
BioDelivery Sciences has added to its pipeline of treatments for the pain market, seizing worldwide rights to an experimental topical therapy for painful diabetic neuropathy (PDN) from Arcion Therapeutics.
Raleigh, NC-based BioDelivery Sciences International has pieced together a $40 million raise from investors, providing the cash needed to wrap a critical late-stage pain therapy program on its way to a planned date with the FDA.
Based on positive results of a pharmacokinetic study, BioDelivery Sciences is planning a second-quarter 2013 submission for marketing approval of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone for the treatment of opioid dependence.
BioDelivery Sciences International is in line for $2.5 million milestone payment from Meda, as Breakyl got its first regulatory clearance in the E.U.
BioDelivery Sciences International has secured a patent for its dissolvable opioid-dependence treatment, and the company is looking to get BEMA Buprenorphine on the market as soon as next year.